Gyre Therapeutics Inc (GYRE)

$10.95 +0.15 (1.39%)
Market Cap 1.01B
Revenue (ttm) 113.45M
Net Income (ttm) -92.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -81.91%
Debt to Equity Ratio 0.00
Volume 48,900
Avg Vol 120,454
Day's Range N/A - N/A
Shares Out 93.52M
Stochastic %K 90%
Beta 1.98
Analysts Strong Buy
Price Target $188.00

Latest News on GYRE

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Nov 13, 2024, 6:00 AM EST - 2 months ago

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

Oct 22, 2024, 4:05 PM EDT - 3 months ago

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

Oct 1, 2024, 4:05 PM EDT - 3 months ago

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Aug 13, 2024, 6:00 AM EDT - 5 months ago

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

Aug 9, 2024, 7:00 AM EDT - 5 months ago

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

Jul 2, 2024, 4:05 PM EDT - 7 months ago

Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology

Jun 18, 2024, 4:05 PM EDT - 7 months ago

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology

Gyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

May 30, 2024, 4:05 PM EDT - 8 months ago

Gyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes

May 28, 2024, 4:05 PM EDT - 8 months ago

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:10 PM EDT - 9 months ago

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mar 26, 2024, 6:00 AM EDT - 10 months ago

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum

Mar 21, 2024, 7:00 AM EDT - 10 months ago

Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

Dec 15, 2023, 9:04 AM EST - 1 year ago

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting

Nov 13, 2023, 7:00 AM EST - 1 year ago

Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting